Ocular Therapeutix (NASDAQ:OCUL) Stock Price Up 9.5% – Time to Buy?
Ocular Therapeutix, Inc. (NASDAQ: OCUL - Get Free Report)'s share price was up 9.5% during mid-day trading on Friday. The stock traded as high as $7.20 and last traded at $7.6970. Approximately 504,364 shares were traded during trading, a decline of 92% from the average daily volume of 6,703,719 shares. The stock had previously closed
Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.29 per share a year ago.
Strength Seen in Ocular Therapeutix (OCUL): Can Its 6.1% Jump Turn into More Strength?
Ocular Therapeutix (OCUL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Biotech outperformance expected to continue in 2026, Baird analysts say
The biotechnology sector's strong fundamentals and robust innovation could continue to drive outperformance this year, according to Baird analysts. The firm noted that while macroeconomic risks such as rising interest rates remain, the biotechnology sector's underlying drivers are supportive.
Ocular Therapeutix (OCUL) Reports Q3 Loss, Tops Revenue Estimates
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.26 per share a year ago.
Wall Street Analysts Believe Ocular Therapeutix (OCUL) Could Rally 82.93%: Here's is How to Trade
The consensus price target hints at an 82.9% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Ocular Therapeutix, Inc. (OCUL) Analyst/Investor Day Transcript
Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Analyst/Investor Day September 30, 2025 2:00 PM EDT Company Participants Pravin Dugel - Executive Chairman, President & CEO Nadia Waheed - Chief Medical Officer Jeffrey Heier, - Chief Scientific Officer Namrata Saroj - Chief Business Officer Jay Robins Peter Kaiser - Chief Development Officer William Slattery - Vice President of Investor Relations Conference Call Participants Arshad Khanani - Sierra Eye Associates Eleonora Lad Adnan Tufail Patricio Schlottmann Tara Bancroft - TD Cowen, Research Division Biren Amin - Piper Sandler & Co., Research Division Colleen Hanley - Robert W. Baird & Co. Incorporated, Research Division Sean McCutcheon - Raymond James & Associates, Inc., Research Division Presentation Operator All right.
Ocular Therapeutix, Inc. (OCUL) Q2 2025 Earnings Call Transcript
Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Q2 2025 Earnings Call August 5, 2025 8:00 AM ET Company Participants Pravin U. Dugel - Executive Chairman, President & CEO William S.
Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.24 per share a year ago.
Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?
Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to loss of $0.24 per share a year ago.
Why Ocular Therapeutix Was Bumping Higher This Week
The market was seeing Ocular Therapeutix (OCUL -6.52%) very positively this week, and that sunny view pushed the company's stock higher.
